Breaking: Pfizer reports strong Q1 2021 earnings, EPS and revenues post strong beats, call details

Pfizer (PFE) reported Q1 2021 earnings before the market opened on Tuesday. Earnings per share (EPS) came in at $0.93 versus a forecast of $0.78. Revenue for the quarter was $14.6 versus a forecast of $13.6 billion.
Pfizer (PFE) will host a conference call to discuss the results at 1400 GMT (1000 EST). The link to the call can be accessed here.
The call will be of heightened interest to all market participants given the COVID-19 pandemic and its effects on global financial markets.
Pfizer (PFE) stock forecast
Pfizer shares are trading at $40.08 in Tuesday's premarket, a gain of 0.63%
At the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this page.
Errors and omissions excepted.
Premium
You have reached your limit of 3 free articles for this month.
Start your subscription and get access to all our original articles.
Author

Ivan Brian
FXStreet
Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.


















